IOT Innovotech Inc

Innovotech Inc. (TSX VENTURE:IOT), today announced that Health Canada has
approved two (2) InnovoSCEPT antimicrobial susceptibility tests for sale in
Canada, an important step in the improved treatment of chronic infections.


The InnovoSCEPT tests join the previously approved, breakthrough product bioFILM
PA(TM) to provide a range of tests for virtually all chronic bacterial
infections that plague human health. "These biofilm tests give doctors
information about the most effective antibiotic treatment to use against a
patient's particular bacterial infection." states Ken Boutilier, President of
Innovotech. "Chronic infections, or those infections that resist eradication or
keep returning, are usually biofilm infections. Before the advent of
Innovotech's tests doctors had to rely on intuition, experience and educated
guesses to prescribe antibiotics for chronic infections. Available tests only
tested for effectiveness against easy to treat, free floating bacteria rather
than the hard to eradicate colonies or biofilms that bacteria build to defend
themselves." InnovoSCEPT tests antibiotics against the particular biofilm that
is infecting a patient, so the chances that a recommended treatment will work
are greatly enhanced.


Antibiotic treatments that do not work cause patients to suffer more, allow the
bacteria to build resistance, and are expensive for the health care system. The
InnovoSCEPT tests have the potential to recommend antibiotics that work the
first time, to improve quality of life for the patient, to shorten hospital
stays, to save the health systems money, and to lengthen the time it takes for
bacteria to develop resistance to antibiotics.


It is estimated that over 17 million patients in the United States suffer from
chronic biofilm infections at a cost to the health care system of over $94
billion. Of these patients 550,000 will die from these infections equal to the
number of patients who die from cancer.


These 2 new products join the growing family of InnovoSCEPT tests for human
health approved in Canada and Israel and marketed by LevPharm in Israel; and
InnovoSCEPT tests for veterinary health marketed worldwide by Spectrum Labs.


About Innovotech Inc.

Innovotech Inc. is a pioneer in the field of biofilm product development,
focused on providing innovative and practical solutions to medical, agricultural
and industrial problems caused by microbial biofilms. Biofilms are organized
communities of microorganisms that exist in virtually every natural environment
and are responsible for a host of diseases in human health, animal health and
agriculture. There are few products or regulatory standards, aside from those of
Innovotech, designed specifically for biofilm-forming organisms. 


Innovotech has a broad range of products that address the issue of biofilms
within a number of different industries, including commercially available
products in three market segments; the MBEC Assay(TM), bioFILM PA(TM),
InnovoSCEPT-Human and InnovoSCEPT-Veterinary tests. The MBEC Assay(TM) is a high
throughput biofilm growth device that was recently approved as an ASTM
International standard. bioFILM PA(TM) and InnovoSCEPT-Human are the first
diagnostic tests to assist physicians in the selection of the most effective
antibiotic treatment for patients with biofilm-based chronic infections, while
the InnovoSCEPT veterinary tests are designed to determine the most effective
antibiotic treatment for chronic infections in both large and small animals. 


Innovotech also has three products in advanced stages of development; Agress(R)
is a unique, environmentally friendly seed treatment and plant spray designed to
protect crops against both bacterial and fungal infections, AgreGuard(TM) is a
unique antimicrobial for coating medical devices such as catheters, and
Sani-Lux(TM) is a light-activated, natural hard surface sanitizer.


Connect with us:

Website: www.innovotech.ca

Blog: www.cf-test.ca

Twitter:www.twitter.com/innovotech

Facebook:www.facebook.com/innovotech

This document may contain forward-looking statements that are predictive in
nature and subject to risks and uncertainties that cannot be predicted or
quantified; consequently, actual results may differ materially from past results
and those expressed or implied by any forward-looking statements. Factors that
could cause or contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of predicting
regulatory outcomes; changes in the value of the Canadian dollar; the Company's
reliance on a small number of customers including government organizations;
fluctuations in operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships; uncertainty
related to intellectual property protection and potential costs associated with
its defense; the Company's exposure to lawsuits and other matters beyond the
control of management. Should known or unknown risks or uncertainties
materialize, or should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company undertakes no
obligation to publicly make or update any forward-looking statements, except as
required by applicable law.

Innovotech (TSXV:IOT)
Historical Stock Chart
From Apr 2024 to May 2024

Innovotech (TSXV:IOT)
Historical Stock Chart
From May 2023 to May 2024